I've been writing and editing stories for almost two decades that help people use technology and productivity techniques to work better, live better, and protect their privacy and personal data. As ...

Intended for high school seniors, this annual event will highlight opportunities offered by Smith College for African American, Asian American, Latin American, Native American, and/or first-generation ...

Whether you're creating short videos for social media or working on a feature-length film, the right editing software is essential. We've tested and rated the best video editing software for all types ...

C tool with 125 MS/s sampling—perfect for fieldwork, classrooms, or your desktop Compact, cost-effective i.MX 91 development board optimized for embedded Linux development Building an indoor ...

Blockbuster drugs are launched by the pharmaceuticals industry to great fanfare — with promises of treating intractable illness and often with a stratospheric price tag. Yet, despite the hype and cost ...

SAN FRANCISCO, Sept 18 (Reuters) - Microsoft (MSFT.O), opens new tab on Thursday said it plans to build a second massive artificial intelligence data center in Wisconsin, bringing its spending in the ...

Helping news, media, brands and institutions leverage our world-class content and cutting-edge services to drive value to their audiences and business. It was 5-year-old Tod’s first time competing in ...

An inherent principle of publication is that others should be able to replicate and build upon the authors' published claims. A condition of publication in a Nature Portfolio journal is that authors ...

We're dedicated to nurturing and guiding the future generation of physicians and physician-scientists, recognizing that our trainees are the cornerstone of our nation's healthcare system.

Kash Patel’s Epstein files problem is not going away. Over two days of hearings, Democrats hammered the FBI director — who once advocated for the wholesale release of the files connected to convicted ...

The FDA's new program could expedite Orforglipron's approval, reducing review time to 1-2 months for high-burden condition treatments. Orforglipron, a non-peptide oral GLP-1 receptor agonist, has ...